ARVINAS, INC. Long-Term Debt, Maturity, after Year Five
ARVINAS, INC. (ARVN) had Long-Term Debt, Maturity, after Year Five of $200.00 thousand as of 2022-12-31, per its 10-K filed 2023-02-23.
Discontinued › Notes › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive · last filed 2023-02-23
- 2022-12-31: Long-Term Debt, Maturity, after Year Five $200.00K.
- 2021-12-31: Long-Term Debt, Maturity, after Year Five $400.00K.
- 2020-12-31: Long-Term Debt, Maturity, after Year Five $1.14M.
- 2019-12-31: Long-Term Debt, Maturity, after Year Five $1.53M.
| Period end | Long-Term Debt, Maturity, after Year Five |
|---|---|
| 2022-12-31 | $200.00K 10-K · filed 2023-02-23 |
| 2021-12-31 | $400.00K 10-K · filed 2022-02-28 |
| 2020-12-31 | $1.14M 10-K · filed 2021-03-01 |
| 2019-12-31 | $1.53M 10-K · filed 2020-03-16 |
| 2018-12-31 | $1.91M 10-K · filed 2019-03-26 |
| 2018-09-30 | $2.00M 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |